Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

1.

Sulfadiazine-induced crystal nephropathy: a new 'old' problem.

Slade H, Mulroy E, Ussher J, Putt T, Schollum J, Walker R.

Nephrology (Carlton). 2015 Jul;20(7):511. doi: 10.1111/nep.12428. No abstract available.

PMID:
26063491
2.

A cross-sectional study of autoantibody profiles in the Waikato systemic sclerosis cohort, New Zealand.

Chang WS, Schollum J, White DH, Solanki KK.

Clin Rheumatol. 2015 May 29. [Epub ahead of print]

PMID:
26022620
3.

Spontaneous perinephric haemorrhage in an end-stage renal disease patient with multiple renal pseudoaneurysms.

Mulroy E, Schollum J, Putt T, Walker R.

Nephrology (Carlton). 2015 Jun;20(6):441. doi: 10.1111/nep.12415. No abstract available.

PMID:
25900389
4.

GFR may not accurately predict aspects of proximal tubule drug handling.

Putt TL, Duffull SB, Schollum JB, Walker RJ.

Eur J Clin Pharmacol. 2014 Oct;70(10):1221-6. doi: 10.1007/s00228-014-1733-7. Epub 2014 Aug 20.

PMID:
25135059
5.

Rationale and design of the Myocardial Microinjury and Cardiac Remodeling Extension Study in the Sodium Lowering in Dialysate trial (Mac-SoLID study).

Dunlop JL, Vandal AC, de Zoysa JR, Gabriel RS, Gerber LM, Haloob IA, Hood CJ, Irvine JH, Matheson PJ, McGregor DO, Rabindranath KS, Schollum JB, Semple DJ, Marshall MR.

BMC Nephrol. 2014 Jul 21;15:120. doi: 10.1186/1471-2369-15-120.

6.

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.

Yale JF, Bakris G, Cariou B, Nieto J, David-Neto E, Yue D, Wajs E, Figueroa K, Jiang J, Law G, Usiskin K, Meininger G; DIA3004 Study Group.

Diabetes Obes Metab. 2014 Oct;16(10):1016-27. doi: 10.1111/dom.12348. Epub 2014 Jul 22.

PMID:
24965700
7.

Utility of Urinary Biomarkers in Predicting Loss of Residual Renal Function: The balANZ Trial.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Clarke M, Topley N; balANZ Trial Investigators.

Perit Dial Int. 2015 Mar-Apr;35(2):159-71. doi: 10.3747/pdi.2013.00170. Epub 2014 Apr 7.

PMID:
24711637
8.

Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury?

Berney-Meyer L, Hung N, Slatter T, Schollum JB, Kitching AR, Walker RJ.

Nephrology (Carlton). 2014 Jun;19(6):359-65. doi: 10.1111/nep.12226.

PMID:
24629073
9.

Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease.

Hoye NA, Baldi JC, Putt TL, Schollum JB, Wilkins GT, Walker RJ.

Clin Kidney J. 2014 Feb;7(1):3-10. doi: 10.1093/ckj/sft130. Epub 2013 Nov 8.

10.

Dialysate interleukin-6 predicts increasing peritoneal solute transport rate in incident peritoneal dialysis patients.

Cho Y, Johnson DW, Vesey DA, Hawley CM, Pascoe EM, Clarke M, Topley N; balANZ Trial Investigators.

BMC Nephrol. 2014 Jan 10;15:8. doi: 10.1186/1471-2369-15-8.

11.

Dialysis outcomes in those aged ≥65 years.

Walker R, Derrett S, Campbell J, Marshall MR, Henderson A, Schollum J, Williams S, McNoe B.

BMC Nephrol. 2013 Aug 14;14:175. doi: 10.1186/1471-2369-14-175.

12.

Chronic interstitial fibrosis in the rat kidney induced by long-term (6-mo) exposure to lithium.

Walker RJ, Leader JP, Bedford JJ, Gobe G, Davis G, Vos FE, deJong S, Schollum JB.

Am J Physiol Renal Physiol. 2013 Feb 1;304(3):F300-7. doi: 10.1152/ajprenal.00182.2012. Epub 2012 Nov 21.

13.

The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D; balANZ Trial Investigators.

Perit Dial Int. 2012 Sep-Oct;32(5):497-506.

14.

The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.

Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi MG, Tan SH, Voss D; balANZ Trial Investigators.

Nephrol Dial Transplant. 2012 Dec;27(12):4445-53. doi: 10.1093/ndt/gfs314. Epub 2012 Aug 1.

15.

Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database.

Meier FM, Frommer KW, Dinser R, Walker UA, Czirjak L, Denton CP, Allanore Y, Distler O, Riemekasten G, Valentini G, Müller-Ladner U; EUSTAR Co-authors.

Ann Rheum Dis. 2012 Aug;71(8):1355-60. doi: 10.1136/annrheumdis-2011-200742. Epub 2012 May 21.

PMID:
22615460
16.

Adult urinary tract infection.

Schollum JB, Walker RJ.

Br J Hosp Med (Lond). 2012 Apr;73(4):218-23. Review. No abstract available.

PMID:
22585198
17.

Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.

Johnson DW, Brown FG, Clarke M, Boudville N, Elias TJ, Foo MW, Jones B, Kulkarni H, Langham R, Ranganathan D, Schollum J, Suranyi M, Tan SH, Voss D; balANZ Trial Investigators.

J Am Soc Nephrol. 2012 Jun;23(6):1097-107. doi: 10.1681/ASN.2011121201. Epub 2012 Mar 22.

18.

"It was just an unconditional gift." Self reflections of non-directed living kidney donors.

Tong A, Craig JC, Wong G, Morton J, Armstrong S, Schollum J, Cross N.

Clin Transplant. 2012 Jul-Aug;26(4):589-99. doi: 10.1111/j.1399-0012.2011.01578.x. Epub 2012 Jan 17.

PMID:
22251271
19.

Dietary sodium loading in normotensive healthy volunteers does not increase arterial vascular reactivity or blood pressure.

Todd AS, Macginley RJ, Schollum JB, Williams SM, Sutherland WH, Mann JI, Walker RJ.

Nephrology (Carlton). 2012 Mar;17(3):249-56. doi: 10.1111/j.1440-1797.2011.01550.x.

PMID:
22171802
20.

Glycated albumin is the preferred marker for assessing glycaemic control in advanced chronic kidney disease.

Vos FE, Schollum JB, Walker RJ.

NDT Plus. 2011 Dec;4(6):368-75. doi: 10.1093/ndtplus/sfr140. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk